Funded Projects › FP7
ACTION · Aggression in Children: Unraveling gene-environment interplay to inform Treatment and InterventiON strateg
Aggression inflicts a huge personal, psychological and financial burden on affected individuals, their relatives, and society at large. Despite large scientific, preventive, and treatment investments, no decrease in aggressive behavior is seen. This calls for a shift to new approaches. By capitalising on comprehensive longitudinal cohorts, recent advances in genetic, biological, epidemiological, and clinical fields, and combining such interdisciplinary expertise the ACTION consortium will dissect the etiology and pathogenesis of aggression. Based on new insights, ACTION will inform the development of novel diagnostic tools and causative targets and guide the development of treatment and prevention strategies. ACTION is built on interrelated work packages with a focus on a) clinical epidemiology and current classification and treatment problems; b) genetic epidemiology, including Genome Wide Association studies and epigenetics; c) gene-environment correlation and interaction; d) biomarkers and metabolomics. ACTION will deliver an overarching framework that combines a thorough understanding of pathways leading to aggression with a map of current gaps, best practices on clinical, ethical, legal, and social issues. Based on this framework, ACTION will develop novel biomarkers suitable for large-scale applications in children and combine biomarker data with new insights into the effects of gender, age, and comorbidity. ACTION will provide guidance in optimising current intervention programs and deliver new biological targets to pave the way for novel therapeutic interventions. ACTION will provide a decision tree to guide personalised intervention programmes and will have direct and sustained impact on reducing paediatric aggression. Its overarching aim is to reduce aggression by developing approaches that take individual differences in genetic and environmental susceptibility into account, thereby leading to better understanding of personalised intervention programs.
Consortium · 12 organisations
STICHTING VU
NL · €1,697,459
ACADEMISCH ZIEKENHUIS LEIDEN
NL · €392,100
GOOD BIOMARKER SCIENCES BV
NL · €894,963
UNIVERSITEIT LEIDEN
NL · €419,452
HELSINGIN YLIOPISTO
FI · €496,720
DIAGENODE
BE · €22,267
University of Notre Dame du Lac
US · €270,009
UNIVERSITA DEGLI STUDI DI CAGLIARI
IT · €475,947
QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
AU
KAROLINSKA INSTITUTET
SE · €501,280
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €278,700
KING'S COLLEGE LONDON
UK · €550,183
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.